Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What to do, when a Taltz® (ixekizumab) dose is missed?
The Taltz European Summary of Product Characteristics does not contain a specific recommendation about what to do when a patient forgets a dose of ixekizumab.
cFAQ
cFAQ
UK_cFAQ_IXE308_MISSED_DOSE_PsO_PEDS_PsA_axSpA
en-GB
Table of Contents
Additional information on a missed dose
- The US Taltz package insert states that if a dose is missed, the dose should be administered as soon as possible. Thereafter, resume dosing at the regular scheduled time.1
Detailed Information from the Clinical Trials
The following information describes the procedure in the clinical trials with ixekizumab. The treatment decision remains at the discretion of the treating physician.
Plaque Psoriasis
- For the pivotal UNCOVER adult psoriasis clinical trials, injections not administered on the scheduled day were to be administered
- within 1 to 3 days of the scheduled day during the induction period (week 0-12), and
- within 5 days of the scheduled day after week 12.2
- For the IXORA-PEDS pediatric psoriasis clinical trial, injections not administered on the scheduled day were to be administered within 5 days of the originally scheduled day. Dates of subsequent study visits were not to be modified according to the delay.3
Psoriatic Arthritis
- For the pivotal SPIRIT Psoriatic Arthritis clinical trials, injections not administered on the scheduled day were to be administered
- within 3 to 4 days of the scheduled day from week 0 to week 24, and
- within 4 to 5 days of the scheduled day after week 24.3
Radiographic axial Spondyloarthritis
- For the pivotal COAST-V Ankylosing Spondylitis (AS)/ radiographic axial Spondyloarthritis (r-axSpA) clinical trial, injections not administered on the scheduled day were to be administered
- within 3 days of the scheduled day from week 0 to week 16, and
- within 5 days of the scheduled day after week 16.3
- For the pivotal COAST-W AS/r-axSpA clinical trial, the missed injection was to be administered as soon as possible but not within 5 days of the next scheduled dose. Injections were to be at least 5 days apart and subsequent study visits were not to be modified according to this delay.3
Non-radiographic axial Spondyloarthritis
- For the pivotal COAST-X non-radiographic axial Spondyloarthritis clinical trial, the missed injection was to be administered as soon as possible but not within 5 days of the next scheduled dose. Injections were to be at least 5 days apart and subsequent study visits were not to be modified according to this delay.3
References
1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 15 April 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays